Evidence map›Paper›PMID 21159799›Full record

ArticleHuman molecular genetics2011

A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice.

Satoko Tokuda, Connie L Mahaffey, Bobby Monks, Christian R Faulkner, Morris J Birnbaum, Steve C Danzer, Wayne N Frankel

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. 4E-BP2-dependent translation in parvalbumin neurons controls epileptic seizure threshold.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Cortical Seizures inInternational journal of molecular sciences · 2019
    Article
  12. Mechanistic Target of Rapamycin Pathway in Epileptic Disorders.Journal of Korean Neurosurgical Society · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Satoko TokudaThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Connie L Mahaffey
Bobby Monks
Christian R Faulkner
Morris J Birnbaum
Steve C Danzer
Wayne N Frankel
Jackson Laboratory · USCincinnati Children's Hospital Medical Center · USUniversity of Pennsylvania · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
PRODUCTION AND SCREENING OF MOUSE NEUROLOGICAL MUTATIONSU01NS041215 · NINDS · JACKSON LABORATORY · PI FRANKEL, WAYNE N. · 2000 to 2004
$16.4M
GENETIC DETERMINANTS OF EPILEPSY IN MURINE SYSTEMSR01NS031348 · NINDS · JACKSON LABORATORY · PI SANDS, TRISTAN T · 1993 to 2025
$11.5M
Selective disruption of hippocampal dentate granule cells in autism: impact of PTR01NS065020 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI DANZER, STEVE C · 2009 to 2023
$6.1M
Genetic Determinants of Epilepsy in Murine SystemsR37NS031348 · NINDS · JACKSON LABORATORY · PI FRANKEL, WAYNE N. · 2014 to 2020
$5.8M
THE ROLE OF THE AKT/PKB SIGNALING IN INSULIN ACTIONR01DK056886 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BIRNBAUM, MORRIS J · 2000 to 2014
$5.3M
NCI NIH HHS CA034196NCI NIH HHS P30 CA034196NIDDK NIH HHS DK56886NIDDK NIH HHS R01 DK056886NINDS NIH HHS NS031348NINDS NIH HHS NS041215NINDS NIH HHS NS-065020NINDS NIH HHS R01 NS031348NINDS NIH HHS R01 NS065020NINDS NIH HHS R37 NS031348NINDS NIH HHS U01 NS41215
6 · The paper itself

Abstract

In a phenotype-driven mutagenesis screen, a novel, dominant mouse mutation, Nmf350, caused low seizure threshold, sporadic tonic-clonic seizures, brain enlargement and ectopic neurons in the dentate hilus and molecular layer of the hippocampus. Genetic mapping implicated Akt3, one of four candidates within the critical interval. Sequencing analysis revealed that mutants have a missense mutation in Akt3 (encoding one of three AKT/protein kinase B molecules), leading to a non-synonymous amino acid substitution in the highly conserved protein kinase domain. Previous knockout studies showed that Akt3 is pivotal in postnatal brain development, including a smaller brain, although seizures were not observed. In contrast to Akt3(Nmf350), we find that Akt3 null mice exhibit an elevated seizure threshold. An in vitro kinase assay revealed that Akt3(Nmf350) confers higher enzymatic activity, suggesting that Akt3(Nmf350) might enhance AKT signaling in the brain. In the dentate gyrus of Akt3(Nmf350) homozygotes, we also observed a modest increase in immunoreactivity of phosphorylated ribosomal protein S6, an AKT pathway downstream target. Together these findings suggest that Akt3(Nmf350) confers an increase of AKT3 activity in specific neuronal populations in the brain, and a unique dominant phenotype. Akt3(Nmf350) mice provide a new tool for studying physiological roles of AKT signaling in the brain, and potentially novel mechanisms for epilepsy.

Indexed as

Disease SusceptibilityMutation, MissenseAmino Acid SequenceAnimalsCell LineFemaleHumansMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMolecular Sequence DataPhosphorylationProto-Oncogene Proteins c-aktRibosomal Protein S6 KinasesAkt3 protein, mouseProto-Oncogene Proteins c-aktRibosomal Protein S6 Kinases

Identifiers

PMID21159799
PMCPMC3033189
OpenAlexW2142093789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.